Abstract:<p>An estimated 466 million people suffer from hearing loss worldwide. Sensorineural hearing loss is characterized by degeneration of key structures of the sensory pathway in the cochlea such as the sensory hair cells, the primary auditory neurons and their synaptic connection to the hair cells – the ribbon synapse. Various strategies to protect or regenerate these sensory cells and structures are the subject of intensive research. Yet despite recent advances in our understandings of the capacity of the cochlea for repair and regeneration there are currently no pharmacological or biological interventions for hearing loss. Current research focusses on localized cochlear drug, gene and cell-based therapies. One of the more promising drug-based therapies is based on neurotrophic factors for the repair of the ribbon synapse after noise exposure, as well as preventing loss of primary auditory neurons and regrowth of the auditory neuron fibers after severe hearing loss. Drug therapy delivery technologies are being employed to address the specific needs of neurotrophin and other therapies for hearing loss that include the need for high doses, long-term delivery, localised or cell-specific targeting and techniques for their safe and efficacious delivery to the cochlea. Novel biomaterials are enabling high payloads of drugs to be administered to the cochlea with subsequent slow-release properties that are proving to be beneficial for treating hearing loss. In parallel, new gene therapy technologies are addressing the need for cell specificity and high efficacy for the treatment of both genetic and acquired hearing loss with promising reports of hearing recovery. Some biomaterials and cell therapies are being used in conjunction with the cochlear implant ensuring therapeutic benefit to the primary neurons during electrical stimulation. This review will introduce the auditory system, hearing loss and the potential for repair and regeneration in the cochlea. Drug delivery to the cochlea will then be reviewed, with a focus on new biomaterials, gene therapy technologies, cell therapy and the use of the cochlear implant as a vehicle for drug delivery. With the current pre-clinical research effort into therapies for hearing loss, including clinical trials for gene therapy, the future for the treatment for hearing loss is looking bright.</p>

Genetic Effects on Sensorineural Hearing Loss and Evidence-based Treatment for Sensorineural Hearing Loss

Cochlear Gene Therapy for Sensorineural Hearing Loss: Current Status and Major Remaining Hurdles for Translational Success.

Stem Cells and Gene Therapy in Progressive Hearing Loss: the State of the Art

Gene Therapy for Human Sensorineural Hearing Loss

Genetic Hearing Loss and Gene Therapy

Recent advances and future challenges in gene therapy for hearing loss

Advances in the Study of Etiology and Molecular Mechanisms of Sensorineural Hearing Loss

Recent advances in genetic etiology of non-syndromic deafness in children

Research progress on the treatment and nursing of sensorineural hearing loss

Advancements and future prospects of adeno-associated virus-mediated gene therapy for sensorineural hearing loss

New molecular therapies for the treatment of hearing loss

Current AAV-mediated Gene Therapy in Sensorineural Hearing Loss

Advances in Cochlear Implantation for Hereditary Deafness Caused by Common Mutations in Deafness Genes

Deafness: from genetic architecture to gene therapy

Non-Syndromic Hearing Loss and High-Throughput Strategies to Decipher Its Genetic Heterogeneity

Biomaterials as a new option for treating sensorineural hearing loss.

Gene Therapy for Inherited Hearing Loss: Updates and Remaining Challenges

Advances in Gene Therapy Hold Promise for Treating Hereditary Hearing Loss

Stem cell therapy in sensorineural hearing loss: a systematic review

Regenerative Therapy for Sensorineural Hearing Loss: Recent Progress and Future Directions

Milestones toward cochlear gene therapy for patients with hereditary hearing loss